The FDA’s latest compounding move is not flashy consolidation news. It will not change tomorrow’s appointment schedule. But for independent veterinary practices, it deserves a spot on the owner’s desk because it touches something very practical: how you source the compounded medications your doctors rely on when approved products do not fit the patient in front of them.

On August 27, FDA announced draft Guidance for Industry #256B, focused on animal drugs compounded from bulk drug substances in federally registered facilities operating under current good manufacturing practice, or CGMP. Public comments are due by November 27, 2026.

That matters because compounding is one of those everyday clinical tools that can get treated as a pharmacy problem until it suddenly becomes a continuity-of-care problem. The independent-practice advantage is judgment: knowing the patient, explaining the tradeoffs, and choosing a practical plan. The new draft is a reminder that the business side has to support that judgment with cleaner vendor review, better records, and a clear medication backup plan.

What FDA is trying to clarify

FDA’s existing GFI #256 lays out when the agency generally does not intend to take enforcement action involving certain animal drugs compounded from bulk drug substances. The new draft, #256B, would add recommendations for federally registered facilities—including certain outsourcing-style facilities—that may not be state-licensed pharmacies but are registered with FDA under federal drug manufacturing provisions.

FDA says the policy is aimed at circumstances where no other medically appropriate treatment option exists. That is an important boundary. This is not a blanket green light for cheap copies of approved drugs. FDA’s compounding materials continue to emphasize that drugs made from bulk substances are not FDA-approved and have not gone through the same review for safety, effectiveness, manufacturing, labeling, packaging, or post-market controls.

For practices, the practical question is not, “Can we still compound?” In many cases, yes. FDA’s Q&A says veterinarians can still prescribe compounded animal drugs, and GFI #256 recognizes situations where an approved, conditionally approved, or indexed drug may not work for a particular patient. The real question is, “Can we show why this compounded product, this source, and this dispensing pathway made medical sense?”

Why independents should pay attention now

Large groups often centralize purchasing, legal review, and vendor approval. Independents may have a shorter chain of command, which is a strength—but only if someone owns the process.

Start with an inventory review. Pull a list of compounded medications you keep as office stock or prescribe regularly. Separate patient-specific prescriptions from office-stock items. Then flag any medication compounded from a bulk drug substance, especially if it has an approved animal or human product that could be used as labeled or extralabel.

Next, look at the FDA’s bulk drug substance lists. Some substances are under review; others have been reviewed and not listed. FDA’s decisions often turn on whether approved alternatives are available, whether the drug is needed urgently, and whether a patient-specific prescription would be enough. That is exactly the kind of nuance practice owners want built into protocols before an associate is trying to solve it during a packed afternoon.

Vendor review is the second step. If a supplier describes itself as a 503B outsourcing facility, federally registered facility, or CGMP operation, ask for documentation and make sure your team understands what that status does—and does not—mean. A vendor’s scale or slick ordering portal is not the same thing as a practice-level rationale for use.

The third step is medical-record hygiene. The Federal Register notice discusses documentation of the prescribing veterinarian’s medical rationale and the reason a bulk drug substance is being used as the active-ingredient source. FDA suggests veterinarians are often already keeping this kind of rationale as part of normal medical records. That may be true in principle, but many practices know the reality: the reasoning may live in the doctor’s head, a callback note, or a pharmacy message rather than a consistent chart field.

A simple template can help: approved options considered; why they were not medically appropriate; why the compounded form was needed; whether the product was patient-specific or office stock; and what client counseling was provided.

The takeaway

This draft guidance is still a draft. It does not require panic buying, abandoning useful compounded medications, or turning doctors into regulatory clerks.

It does call for ownership. Independent practices should use the comment window to identify medications that are essential to patient care, tell FDA where the draft creates workable clarity or real-world friction, and tighten internal systems before final guidance arrives.

Compounding has always lived at the intersection of medicine, pharmacy, access, and risk. For independents, the opportunity is to keep that intersection clinician-led—not vendor-led, not crisis-led, and not left to chance.